Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabinoid and adenosine A<sub>2A</sub> receptor crosstalk regulates postnatal and adult hippocampal neurogenesis.

British journal of pharmacology·2026
Same author

Early, sex-dependent and progressive proteomic imbalance in the amygdala during Alzheimer´s disease continuum.

Biology of sex differences·2026
Same author

The landscape of taste receptors in glioblastoma.

Biochemical pharmacology·2026
Same author

NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopathy mouse model.

Redox biology·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Thrombospondin-1 regulates synaptic transmission in hippocampal field CA2 and social behavior in mice.

Neurobiology of disease·2025

Related Experiment Video

Updated: Apr 25, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

754

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.

Ester Aso1, Alexandre Sánchez-Pla2, Esteban Vegas-Lozano3

  • 1Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.

Journal of Alzheimer'S Disease : JAD
|August 16, 2014
PubMed
Summary

Cannabis compounds delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) improved memory and reduced learning deficits in an Alzheimer

Keywords:
Alzheimer's diseaseanimal modelcannabidioltetrahydrocannabinoltherapy

More Related Videos

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

754
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) plaques and neuroinflammation.
  • The endogenous cannabinoid system is a potential therapeutic target for AD.
  • Cannabis-derived compounds like THC and CBD have shown therapeutic potential.

Purpose of the Study:

  • To investigate the therapeutic effects of THC and CBD, individually and in combination, on Alzheimer's disease.
  • To evaluate the impact of these cannabinoids on cognitive function, Aβ pathology, and neuroinflammation in a mouse model of AD.
  • To explore the molecular mechanisms underlying cannabinoid-induced neuroprotection.

Main Methods:

  • Administration of THC, CBD, or a combination of both to AβPP/PS1 transgenic mice during the early symptomatic stage.
  • Assessment of cognitive function using memory and learning tests.
  • Analysis of brain tissue for Aβ peptide levels, plaque composition, astrogliosis, microgliosis, and inflammatory markers.
  • Genome-wide gene expression profiling to identify molecular targets.

Main Results:

  • THC and CBD, particularly in combination, preserved memory and reduced learning impairment in AD mice.
  • The THC + CBD treatment significantly decreased soluble Aβ42 peptide levels and altered plaque composition.
  • Cannabinoid treatment reduced neuroinflammation, including astrogliosis and microgliosis, with the combination showing the most pronounced effects.
  • Gene expression analysis identified thioredoxin 2 and Wnt16 as key molecular targets of THC + CBD treatment.

Conclusions:

  • The combination of THC and CBD demonstrates a superior therapeutic profile compared to individual components for Alzheimer's disease.
  • Cannabinoids, through anti-inflammatory actions and modulation of Aβ pathology, offer a promising therapeutic strategy for AD.
  • Further research into cannabis-based medicines is warranted for the potential treatment of Alzheimer's disease.